1. Biomarker Editorial: The Many Lives of the Biomarker

   • David S. Lester

   Biomarker 30 December 2007 Pages: 551 - 553

2. Implementation of a Biomarker into Drug Development: Example of Identifying the Right Imaging “Tool” for an Oncology Study

   • Barry T. Peterson
   • Timothy J. McCarthy
   • Philip Murphy

   Biomarker 30 December 2007 Pages: 555 - 560

3. Imaging Biomarker Applications in Oncology Drug Development

   • Janet C. Miller
   • Homer H. Pien
   • A. Gregory Sorensen

   Biomarker 30 December 2007 Pages: 561 - 572

4. Molecular Biomarkers

   • Omar F. Laterza
   • Ronald C. Hendrickson
   • John A. Wagner

   Biomarker 30 December 2007 Pages: 573 - 585

5. A Regulatory Perspective on Validation of Surrogate Endpoints

   • Lawrence J. Lesko

   Biomarker 30 December 2007 Pages: 587 - 594

6. Interrater Reliability for Multiple Raters in Clinical Trials of Ordinal Scale

   • Jungo Sawa
   • Toshihiko Morikawa

   Biostatistics 30 December 2007 Pages: 595 - 605

7. Notes on Test Equality in Stratified Noncompliance Randomized Trials

   • Kung-Jong Lui

   Biostatistics 30 December 2007 Pages: 607 - 618

8. Sex Differences in QT Interval Variability and Implication on Sample Size of Thorough QT Study

   • Lu Zhang
   • Brian P. Smith

   Biostatistics 30 December 2007 Pages: 619 - 627

9. Some Comments on Improving Collaboration Skills of the Statistician on a Drug Development Team

   • James R. Johnson

   Biostatistics 30 December 2007 Pages: 629 - 632

10. Using Data Mining to Predict Safety Actions from FDA Adverse Event Reporting System Data

    • Alan M. Hochberg
    • Stephanie J. Reisinger
    • Kevin Hall

    Biostatistics 30 December 2007 Pages: 633 - 643

11. The Demographic, Practice, and Prescribing Characteristics of US Clinical Investigators

    • Harold E. Glass
    • Daniel P. Beaudry

    Drug Development 30 December 2007 Pages: 645 - 651

12. The December Effect in FDA Drug Approvals: Assessing the Submissions Echo Hypothesis

    • James B. Graham
    • Ernst R. Berndt

    Drug Development 30 December 2007 Pages: 653 - 659

13. Development of an Established Name: Analyzing Stem Based United States Adopted Naming

    • Patrick M. Carpenter
    • Robyn A. Bruce

    Regulatory Affairs 30 December 2007 Pages: 661 - 672

14. How to Improve Complex Drug Development? A Critical Review of FDA Advisory Meetings

    • Pol F. Boudes

    Regulatory Affairs 30 December 2007 Pages: 673 - 684

15. A Statistician’s Viewpoint of Responders in the Treatment of Neuropathic Pain

    • Ling Chen

    Continuing Education 30 December 2007 Pages: 685 - 689